Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity
Authors
Keywords
-
Journal
OncoImmunology
Volume 4, Issue 3, Pages e988460
Publisher
Informa UK Limited
Online
2015-01-08
DOI
10.4161/2162402x.2014.988460
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Novel Bispecific Antibodies Increase T-Cell Cytotoxicity against Pancreatic Cancer Cells
- (2014) H.-H. Oberg et al. CANCER RESEARCH
- The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies
- (2014) Mohsen Vosooghi et al. Expert Opinion on Drug Discovery
- Comparative Characterization of Stroma Cells and Ductal Epithelium in Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma
- (2014) Ole Helm et al. PLoS One
- Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties
- (2013) Namita Kundu et al. BREAST CANCER RESEARCH AND TREATMENT
- The stromal compartments in pancreatic cancer: Are there any therapeutic targets?
- (2013) Serena Lunardi et al. CANCER LETTERS
- A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis
- (2013) Xinrong Ma et al. OncoImmunology
- Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells
- (2012) Ayano Kabashima-Niibe et al. CANCER SCIENCE
- Cell Intrinsic Role of COX-2 in Pancreatic Cancer Development
- (2012) R. Hill et al. MOLECULAR CANCER THERAPEUTICS
- Prostaglandin E2 and T cells: friends or foes?
- (2011) Vinatha Sreeramkumar et al. IMMUNOLOGY AND CELL BIOLOGY
- PGE2 inhibits natural killer and γδ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling
- (2010) Ludovic Martinet et al. BIOCHEMICAL PHARMACOLOGY
- A novel antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models
- (2010) Q Chen et al. BRITISH JOURNAL OF PHARMACOLOGY
- Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes
- (2010) Yunyun Su et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer
- (2010) Allan Lipton et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Bioavailability Enhancement of Curcumin by Complexation with Phosphatidyl Choline
- (2010) Nishant Kumar Gupta et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Toll-like Receptors 3 and 7 Agonists Enhance Tumor Cell Lysis by Human T Cells
- (2009) H. Shojaei et al. CANCER RESEARCH
- A regulatory cross-talk between Vγ9Vδ2 T lymphocytes and mesenchymal stem cells
- (2009) Ludovic Martinet et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Toll-Like Receptor Expression and Function in Subsets of Human γδ T Lymphocytes
- (2009) K. Pietschmann et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Gemcitabine Plus Celecoxib in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
- (2008) Tomislav Dragovich et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Prevention of Both Direct and Cross-Priming of Antitumor CD8+ T-Cell Responses following Overproduction of Prostaglandin E2 by Tumor Cells In vivo
- (2008) M. Ahmadi et al. CANCER RESEARCH
- Selective Inhibition of Cyclooxygenase-2 Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo
- (2008) Xuan-Fu Xu et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now